Soluble CD40 in plasma and malignant pleural effusion with non‐small cell lung cancer: A potential marker of prognosis

Mu, Chuanyong; Qin, Pang-Xue; Qu, Qiuxia; Chen, Cheng; Huang, Jianan

doi:10.1016/j.cdtm.2015.02.010

Cited by 14 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…163 Soluble CD40 (sCD40) levels are increased in MPE and are indicative of poor prognosis. 164 High concentrations of sCD40 inhibit B cell function by competing for CD154 on T lymphocytes, limiting T cell help and promoting another means of immune evasion. 164 B cell B7-H4 expression is also elevated and is associated with poor prognosis for patients with metastatic pleural adenocarcinoma.…”

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

“…164 High concentrations of sCD40 inhibit B cell function by competing for CD154 on T lymphocytes, limiting T cell help and promoting another means of immune evasion. 164 B cell B7-H4 expression is also elevated and is associated with poor prognosis for patients with metastatic pleural adenocarcinoma. 165 Interestingly, anti-B7-H4 mAb effectively suppressed pleural effusion formation in a mouse model of MPE.…”

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusions, arising from either primary mesotheliomas or secondary malignancies, heralds advanced disease and poor prognosis. Current treatments, including therapeutic thoracentesis and tube thoracostomy, are largely palliative. The immunosuppressive environment within the pleural cavity includes myeloid derived suppressor cells, T-regulatory cells, and dysfunctional T cells. The advent of effective immunotherapy with checkpoint inhibitors and adoptive cell therapies for lung cancer and other malignancies suggests a renewed examination of local and systemic therapies for this malady. Prior strategies reporting remarkable success, including instillation of the cytokine interleukin-2, perhaps coupled with checkpoint inhibitors, should be further evaluated in the modern era.

show abstract

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

Section: Systemic Inflammatory Indicators In Mpe Patientsmentioning

confidence: 99%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Together with their ligands, these molecules have important role to play in tumor immune response and therefore make excellent candidates as immunotherapeutic targets. Elevated levels of the soluble isoforms of some of these TNF superfamily members have been linked to poor disease prognosis in cancer patients . Therefore, extensive studies need to be undertaken to further characterize these soluble isoforms in cancer.…”

Section: Immune Checkpoint Molecules: Regulating the Immune Response mentioning

confidence: 99%

“…sCD226 Serum CD226 increases and interacts with tumor cell expressed CD155 in cutaneous T-cell lymphoma. 138 sCD40 Elevated in pleural effusion of non-small-cell lung cancer (NSCLC) patients that correlates with poor prognosis and disease advancing 145 ; also increased in sera of uremic patients and inhibits B-cell response. 148,149 sCD40L…”

Section: Tnf Superfamily Members In Tumor-specific Immune Response mentioning

confidence: 99%

“…160 soluble isoforms of some of these TNF superfamily members have been linked to poor disease prognosis in cancer patients. [145][146][147] the rate of patient response is still low in most cases. Therefore, it is imperative to look for ways to monitor disease progression and therapeutic end point markers.…”

Section: Tnf Superfamily Members In Tumor-specific Immune Response mentioning

confidence: 99%

See 1 more Smart Citation

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis

2019

View full text Add to dashboard Cite

Background With the recent advances in the understanding of the interaction of the immune system with developing tumor, it has become imperative to consider the immunological parameters for both cancer diagnosis and disease prognosis. Additionally, in the era of emerging immunotherapeutic strategies in cancer, it is very important to follow the treatment outcome and also to predict the correct immunotherapeutic strategy in individual patients. There being enormous heterogeneity among tumors at different sites or between primary and metastatic tumors in the same individual, or interpatient heterogeneity, it is very important to study the tumor‐immune interaction in the tumor microenvironment and beyond. Importantly, molecular tools and markers identified for such studies must be suitable for monitoring in a noninvasive manner. Recent findings Recent studies have shown that the immune checkpoint molecules play a key role in the development and progression of tumors. In‐depth studies of these molecules have led to the development of most of the cancer immunotherapeutic reagents that are currently either in clinical use or under different phases of clinical trials. Interestingly, many of these cell surface molecules undergo alternative splicing to produce soluble isoforms, which can be tracked in the serum of patients. Conclusions Several studies demonstrate that the serum levels of these soluble isoforms could be used as noninvasive markers for cancer diagnosis and disease prognosis or to predict patient response to specific therapeutic strategies.

show abstract

Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma

Zhang

Sun

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

Background: Costimulatory molecules play significant roles in mounting anti-tumor immune responses, and antibodies targeting these molecules are recognized as promising adjunctive cancer immunotherapies. Here, we aim to conduct a first full-scale exploration of costimulatory molecules from the B7-CD28 and TNF families in patients with lung adenocarcinoma (LUAD) and generated a costimulatory moleculebased signature (CMS) to predict survival and response to immunotherapy. Methods: We enrolled 1549 LUAD cases across 10 different cohorts and included 502 samples from TCGA for discovery. The validation set included 970 cases from eight different Gene Expression Omnibus (GEO) datasets and 77 frozen tumor tissues with qPCR data. The underlying mechanisms and predictive immunotherapy capabilities of the CMS were also explored. Results: A five gene-based CMS (CD40LG, TNFRSF6B, TNFSF13, TNFRSF13C, and TNFRSF19) was initially constructed using the bioinformatics method from TCGA that classifies cases as high-vs. low-risk groups per OS. Multivariable Cox regression analysis confirmed that the CMS was an independent prognostic factor. As expected, CMS exhibited prognostic significance in the stratified cohorts and different validation cohorts. Additionally, the prognostic meta-analysis revealed that CMS was superior to the previous signature. Samples in high-and low-risk groups exhibited significantly different tumor-infiltrating leukocytes and inflammatory activities. Importantly, we found that the CMS scores were closely related to multiple immunotherapy biomarkers. Conclusion: We conducted the first and most comprehensive costimulatory molecule landscape analysis of patients with LUAD and built a clinically feasible CMS for prognosis and immunotherapy response prediction, which will be helpful for further optimize immunotherapies for cancer.

show abstract

Soluble CD40 in plasma and malignant pleural effusion with non‐small cell lung cancer: A potential marker of prognosis

Cited by 14 publications

References 24 publications

Making cold malignant pleural effusions hot: driving novel immunotherapies

Making cold malignant pleural effusions hot: driving novel immunotherapies

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis

Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma

Contact Info

Product

Resources

About